Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/21/09 → 8/20/11 |
Funding
- Baxter Healthcare Co: $59,262.00
Recombinant Von Willebrand Factor/Recombinant Factor VIII (rvWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics, Safety, and Tolerability in Type 3 Von Willebrand Disease
- Radulescu, Vlad (PI)